Navigation Links
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
Date:5/1/2013

, NS5a inhibitors, and nucleotide polymerase inhibitors for interferon-free treatment of HCV and Hepatitis B Virus (HBV).

At the same time, wider access to personalised medical treatment is encouraging the uptake of novel, improved therapeutics. The availability of drugs that target viral hepatitis infections according to distinct genetic strains is promoting market development.

HBV and HCV are prevalent among illegal drug users and migrant populations across Europe. However, low awareness means that many affected patients remain untreated.

"Wider access to national counselling programmes and enhancing awareness among high-risk populations such as drug users, infected mothers, and migrants is critical," concludes Chopda. "Such initiatives, together with free screening and reduced treatment costs, will help limit the incidence and impact of Hepatitis B and C."

If you are interested in more information on this research, please send an email to Anna Zanchi , Corporate Communications, at anna.zanchi@frost.com

Analysis of the European Hepatitis B and C Therapeutics Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan's related research services include: European HIV Drugs Market, European Hepatitis B and C Diagnostics Market, U.S. Hepatitis C Market, and U.S HIV/AIDS Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressi
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
4. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
5. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
6. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
9. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
10. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
11. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... China   , July 2, 2015 /PRNewswire/ ... laboratory in Hong Kong has ... BGI Hong Kong facility is the first clinical next-generation-sequencing ... China , meeting the highest standard in clinical ... CFR Part 11 compliant laboratory process, and multiple ISO ...
(Date:7/2/2015)... Agreement reinforces ...   ViiV Healthcare and Desano Pharmaceuticals (Desano) ... China of dolutegravir. The agreement will ... (API), and will allow ViiV Healthcare to offer a competitive ... name Tivicay®) for China and a ...
(Date:7/1/2015)... EDISON, N.J. , July 1, 2015 ... company focused on the development and commercialization of targeted ... the Cantor Fitzgerald Inaugural Healthcare Conference taking place in ... 8, 2015 at Le Parker Meridien Hotel. ... provide an overview of the Company,s business during his ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
(Date:7/3/2015)... ... 2015 , ... " Selfie on a Stick ” was featured on NewsWatch ... products available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, ... documenting memories. , Almost every smartphone has an incredibly powerful camera built into it. ...
(Date:7/3/2015)... ... ... Celebrity Dresses is currently running a promotion through July 30th. Anyone who orders party ... get 10% discount on orders that are over $100. , The promotion is automatically ... or remember redemption codes. , There is a low price guarantee at The ...
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening ... store located in the Lone Star State. The premium frozen yogurt chain was listed ... The store, which opened July 1 at Duke’s Travel Plaza, is located at:, 30176 ...
(Date:7/2/2015)... ... July 02, 2015 , ... When Walker Parking Consultants ... University of Minnesota, they knew it would save the university energy and maintenance ... choice: the total energy savings after installation was an impressive 89 percent, which ...
(Date:7/2/2015)... ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry was ... down to write his first poem, and three years later he was publishing an entire ... worth sharing with the world. "I have always believed that the best way to lift ...
Breaking Medicine News(10 mins):Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
... (AMS), which affects about half of those ascending to heights ... pulmonary or cerebral edema. ,The interest of the general ... past 25 years. This change is partly due to media ... In spite of these apparent changes, it is unknown whether ...
... deadly bird flu since it is still rampant in the region, ... ,"I think countries in this part of the world have ... it, the virus is still circulating," said Shigeru Omi, WHO's regional ... We remain concerned. We must avoid human transmission," he told reporters ...
... patients who have already gone blind in one eye ... and Therapeutics Bulletin (DTB). ,But that is ... (NICE), the body responsible for guiding the NHS on ... (Lucentis) and pegaptanib (Macugen) are licensed in the UK ...
... Biotechnology Co., Ltd. announced that a team led by ... completed a study to assess clinical efficacy, safety, ... for patients with peripheral vascular disease of the lower ... research and treatments for ataxia, cerebral palsy, spinal cord ...
... Those involved in biological weapons programs should be logically liable ... it seems to have happened in US and the Centers ... research laboratory at Texas A&M University to stop all work ... investigating reports of lab workers infected with the category B ...
... personnel involved in the Iraqi invasion of 2003 have ... published ahead of print in Occupational and Environmental Medicine. ... combat to pierce armoured vehicles, and spontaneously combusts on ... breathed in or eaten/drunk in contaminated food/water. ...
Cached Medicine News:Health News:Acute Mountain Sickness may Lead to Pulmonary or Cerebral Edema 2Health News:Bird Flu in Asia Still High Risk Says WHO Official 2Health News:Draft National Policy on Sight-saving Drugs unacceptable 2Health News:Adult Stem Cells Show Promise for Peripheral Vascular Disease 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 2Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 3Health News:Bio-defense Lab Ordered Shut Down as Researchers Get Infected 4
... generation access device - XPOSE 4 - ... The XPOSE 4 Device is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... ACROBAT SUV vacuum stabilizer from Guidant. ... ease of use. The newest members of ... stability with outstanding anastomotic site visibility ... our FlexLink technology on a stronger ...
... in 1992, ABIOMED's BVS 5000 has grown to ... system in the world to support recoverable hearts. ... U.S. Food and Drug Administration for all patients ... to make advances with the BVS 5000, expanding ...
... Dissector has application for use in the ... extraperitoneal spaces such as the retroperitoneal, preperitoneal, ... used in surgical procedures requiring dissection of ... of a quality conduit through a single ...
Medicine Products: